Replies to post #2767 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>The launch of DIC phase II in the EU should happen soon, and with it, the balance sheet should improve by a fraction of $38 million.<

The first significant portion of that $38M probably comes with the completion of Leo’s phase-2 trial in DIC (#msg-14495208).